Drug trials

EXIST3 Affinitor Drug Trial

The Washington University Tuberous Sclerosis Center is participating in the Novartis-sponsored clinical drug trial: “A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (EXIST-3)”.

For additional information, call Olga Novak, clinical research coordinator at 314-454-6120, or see the Clinical Trials.gov website.

Cannabidiol (CBD) Drug Trial

The Washington University Tuberous Sclerosis Center is participating in the GW Pharmaceuticals-Greenwich Biosciences industry-sponsored clinical drug trial: “A Double-blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients with Tuberous Sclerosis Complex who Experience Inadequately-Controlled Seizures (GWPCARE6)”.

For additional information, call Olga Novak, clinical research coordinator at 314-454-6120, or see the Clinical Trials.gov website.